Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study.

Faustino Peron FilhoAndressa de Souza MoreiraAnna Larissa Faria JanesAlexandre Wagner Silva de Souza

Published in: RMD open (2024)

LEF and ADA had comparable outcomes after a median of 15.0 months of follow-up. However, withdrawal from therapy and mild-to-moderate adverse events were only observed in the LEF group.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
ulcerative colitis
stem cells
systemic lupus erythematosus
mesenchymal stem cells
cell therapy